GlaxoSmithKline LLC has been the subject of 3 FDA enforcement/approval records tracked by Argus HQ, compared to 1 for Sanofi-Aventis Deutschland GmbH.
GlaxoSmithKline LLC: 0 warning letters, 2 recalls, 1 approval record, 0 Form 483s.
Sanofi-Aventis Deutschland GmbH: 0 warning letters, 0 recalls, 0 approval records, 1 Form 483.
Side by side
GlaxoSmithKline LLC — Warning letters0
Sanofi-Aventis Deutschland GmbH — Warning letters0
GlaxoSmithKline LLC — Recalls2
Sanofi-Aventis Deutschland GmbH — Recalls0
GlaxoSmithKline LLC — Approval records1
Sanofi-Aventis Deutschland GmbH — Approval records0
GlaxoSmithKline LLC — Form 483s0
Sanofi-Aventis Deutschland GmbH — Form 483s1
Timeline
Cite this comparison
Pre-formatted for a story, footnote, or reference list:
"GlaxoSmithKline LLC vs Sanofi-Aventis Deutschland GmbH: FDA Enforcement Comparison." Argus HQ, accessed August 29, 2026. https://argushq.ai/compare/glaxosmithkline-vs-sanofi-aventis-deutschland-gmbh
Source: FDA.gov (aggregated across Warning Letters, Recalls, Approvals, Form 483s) ↗